|NASDAQ: GLPG||Healthcare / Biotechnology / Belgium|
|38.64||+1.11||+2.96%||Vol 247.97K||1Y Perf -39.49%|
|Mar 31st, 2023 16:00 DELAYED|
|- -||- -%|
|Target Price||55.20||Analyst Rating||Hold 2.71|
|Potential %||42.86||Finscreener Ranking||★★★★ 54.51|
|Insiders Trans % 3/6/12 mo.||-/-/-||Value Ranking||★★★+ 54.27|
|Insiders Value % 3/6/12 mo.||-/-/-||Growth Ranking||★★★★ 58.21|
|Insiders Shares Cnt. % 3/6/12 mo.||-/-/-||Income Ranking||— -|
|Price Range Ratio 52W %||6.89||Earnings Rating||Strong Buy|
|Market Cap||2.55B||Earnings Date||4th May 2023|
Today's Price Range
5 Year PE Ratio Range
|Mngmt Effectiveness||Value||Industry||S&P 500||US Markets|
ROE (5Y Avg)
ROE last 12 Months
ROA (5Y Avg)
ROA last 12 Months
ROC (5Y Avg)
ROC last 12 Months
Return on invested Capital Q
Return on invested Capital Y
|Valuation||Value||Industry||S&P 500||US Markets|
|-1 679 970 000.00|
|Financial Strength||Value||Industry||S&P 500||US Markets|
|Profitability||Value||Industry||S&P 500||US Markets|
|Revenue||Value||Industry||S&P 500||US Markets|
|Dividends||Value||Industry||S&P 500||US Markets|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||4th May 2023|
|Estimated EPS Next Report||-1.83|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||239.94K|
|Avg. Monthly Volume||396.31K|
|Avg. Quarterly Volume||275.03K|
Galapagos NV (NASDAQ: GLPG) stock closed at 38.64 per share at the end of the most recent trading day (a 2.96% change compared to the prior day closing price) with a volume of 247.97K shares and market capitalization of 2.55B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 1407 people. Galapagos NV CEO is Onno van de Stolpe.
The one-year performance of Galapagos NV stock is -39.49%, while year-to-date (YTD) performance is -12.93%. GLPG stock has a five-year performance of -61.27%. Its 52-week range is between 36.165 and 72.11, which gives GLPG stock a 52-week price range ratio of 6.89%
Galapagos NV currently has a PE ratio of 442.20, a price-to-book (PB) ratio of 0.96, a price-to-sale (PS) ratio of 7.39, a price to cashflow ratio of 2.00, a PEG ratio of 2.32, a ROA of 0.11%, a ROC of 0.17% and a ROE of 0.21%. The company’s profit margin is -2.63%, its EBITDA margin is 12.00%, and its revenue ttm is $402.04 Million , which makes it $6.11 revenue per share.
Of the last four earnings reports from Galapagos NV, there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-1.83 for the next earnings report. Galapagos NV’s next earnings report date is 04th May 2023.
The consensus rating of Wall Street analysts for Galapagos NV is Hold (2.71), with a target price of $55.2, which is +42.86% compared to the current price. The earnings rating for Galapagos NV stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Galapagos NV has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Galapagos NV has a Neutral technical analysis rating based on Technical Indicators (ADX : 16.94, ATR14 : 0.92, CCI20 : 59.21, Chaikin Money Flow : 0.18, MACD : -0.52, Money Flow Index : 43.71, ROC : -0.10, RSI : 51.81, STOCH (14,3) : 72.37, STOCH RSI : 1.00, UO : 57.38, Williams %R : -27.63), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Galapagos NV in the last 12-months were:
|Analyst Ratings||Current||1 M ago||3 M ago|
Galapagos NV is a clinical-stage biotechnology company, involved in the discovery and development of small-molecule medicines. The company's product candidate portfolio includes Filgotinib, a JAK1 inhibitor to treat rheumatoid arthritis, Crohn's disease, and ulcerative colitis; novel therapies in cystic fibrosis (a chronic disease that affects the lungs and digestive system); GLPG1690, a selective autotaxin inhibitor with potential application in idiopathic pulmonary disease; GLPG1972 to treat osteoarthritis; and MOR106 to treat atopic dermatitis.
CEO: Onno van de Stolpe
Telephone: +32 15342900
Address: Generaal De Wittelaan L11 A3, Mechelen 2800, , BE
Number of employees: 1 407
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
General partner of Finscreener is SLOVAKODATA, a.s.
Looks like you are using AdBlock.
The revenue earned from advertising enables us to provide the quality content you are trying to reach on this website. In order to view this page, please disable AdBlock or purchase Premium.
Sign in if you already have Premium account.
This could take some time, please wait.